Skip to main content
PLOS One logoLink to PLOS One
. 2022 Dec 22;17(12):e0276379. doi: 10.1371/journal.pone.0276379

Administration of oral dosage forms of medicines to children in a resource limited setting

Abarna Nadeshkumar 1,2,*,#, Gitanjali Sathiadas 3,#, Shalini Sri Ranganathan 2,#
Editor: Vijayaprakash Suppiah4
PMCID: PMC9778530  PMID: 36548310

Abstract

Background

There are many paediatric specific challenges such as lack of age-appropriate dosage forms, inability of young children to swallow tablets and capsules and poor acceptability, during administration of oral dosage forms of medications to children. Parents adopt various methods which they consider best to circumvent this problem. The objective of this study was to describe the administration practice by parents when giving oral dosage forms of medications to children.

Methods

A descriptive cross-sectional study was conducted to assess the administration practice of 1800 oral dosage forms of medications administered to children under the age of 12 years using validated indicators. A pre-tested interviewer-administered questionnaire given to parents or caregivers was used to collect the necessary data. The data were analysed using descriptive statistics.

Results

Data from 1800 oral dosage forms was obtained from 663 children. Of the 1287 solid dosage forms, almost one-third were manipulated by parents at the time of giving the medications to children. They were crushed and dissolved in water given to children. In about 17% of instances safety of water was questionable. In 92% of instances, measuring device was found to be inappropriate.

Conclusion

Administration of oral dosage forms of medications to children is far from ideal and hinders successful use of medications in children.

Introduction

Children do not behave like adults when handling medications. Successful pharmacotherapy in children demands age appropriate prescribing, dispensing and administration of medications. Healthcare professionals face challenges when prescribing and dispensing medications to children [1, 2]. Pharmacotherapy in children will not achieve the intended health outcomes if medications are administered incorrectly. Administration of medications to children by oral route is challenged by children’s inability to swallow solid dosage forms such as tablets and capsules. To our best of knowledge studies reporting practices adopted by parents to administer medications to their children are scarce. This study was aimed to describe the administration practice of oral dosage forms to children under 12 years.

Methods

This was part of a large scale study which investigated the rational use of oral dosage forms (ODFs) in children. The World Health Organisation’s (WHO) methodology on “how to investigate drug use in health facilities?” was adopted in the survey of administering practice of ODFs of medications in children [3].

A cross-sectional descriptive study was conducted in a teaching hospital. Required data were collected from the paediatric clinics. The study sample was the ODFs of medications administered to children under the age of 12 years. Information on ODFs of medications was obtained from prescriptions dispensed with at least one oral dosage form of medications within a month before the day of data collection.

Data were collected over a period of two years from January 2017 after administrative approval. (January 2017 to January 2019).

Sample size and sampling technique

The WHO recommends that there should be at least 600 encounters in a cross-sectional survey with a greater number if possible for drug use studies [3]. Since we were studying the ODFs given to children we equalized one ODF of medication as one encounter. We decided to collect data from a sample of 1800 ODFs using the following inclusion and exclusion criteria.

Inclusion criteria

  1. Prescriptions which had been dispensed with at least one oral dosage form of medication within a month before the day of data collection to children under the age of 12 years

  2. Parents/ guardians providing the data were the ones who gave medications to the child at home

  3. Parents/ guardians must have the prescriptions with them at the time of data collection

Exclusion criteria

  1. Prescriptions without oral dosage forms.

  2. Prescriptions dispensed more than 30 days prior to data collection

Systematic sampling was done to select every other child. Starting point (1st/2nd child) was selected at random. The selected child’s prescription was screened to see whether it fulfils the inclusion criteria. In the absence, prescriptions of consequent children were screened until a prescription satisfying the inclusion criteria was identified. Recruitment of sample selection continued until a total of 1800 ODFs were selected. Data were collected from parents/guardians who visited the clinics using an interviewer-administered questionnaire [S1 Table]. Principal investigator interviewed the parent /guardian while they were waiting to meet the prescriber. Additional information on the reason for repeating of ODFs was also collected. Informed written consent from the parents and assent from child was obtained before data collection.

Indicators

In a prior study, prescribing, dispensing and administration indicators to measure rational use of ODFs to medications had been already developed using modified RAND Corporation / University of California Los Angeles’s (RAND/UCLA) method and validated [4]. The administration indicators focus on the issues related to administration of ODFs. The developed administration indicators were converted to an interviewer-administered questionnaire. This was pre-tested and inter-rater reliability was determined. Numerators and denominators to calculate the indicators were also defined. The administration indicators are given below.

  1. Percentage of instances where the child swallowed the intact tablet/capsule

  2. Percentage of instances where crushed tablet was dissolved and administered

  3. Percentage of liquid oral dosage forms administered using an oral syringe

  4. Percentage of instances where safe water was used in preparing the medicine

  5. Percentage of instances where the prescribed dose is correctly completed

Data entry and analysis

Data were entered in a custom made database. Accuracy of data entry was independently cross-checked. Descriptive statistics was used to calculate the indicators. Children were categorized based on age. Data from term new born [child born on the day of data collection (0 day)] up to 12 years were collected. They were categorized as term new-born (0–27 days), infants and toddlers (1 month to 23 months) pre-school children (2–5 years) and school children (6–11 years) [5]. Tablets, capsules and powders were considered as solid dosage forms, syrups and suspension were taken as liquid dosage forms. Boiled cooled water and bottled drinking water was considered as safe water. Well water was defined as water from hole drilled into the ground to access water contained in an aquifer [6] and water supplied through a water pump. Tube well water was defined as water obtained through a narrow screened tube, pipe or casing that and driven into a subsurface aquifer [7].

Approvals

Ethical approval was obtained from ethics review committee, Faculty of Medicine, University of Colombo, Sri Lanka (EC-15-022). Administrative approval was obtained from the Director/ Teaching Hospital and other relevant administrative authorities.

Results

Data on 1800 ODFs were collected from prescriptions issued to 663 children: Infants and children accounted for 20.5% (N = 136), pre-school children 35.4% (N = 235) and school children 44% (N = 292). Male: female ratio was 1.25.

Tablets (70.6%) followed by syrups (25.9%) were the most commonly prescribed ODFs for this cohort of children (Table 1). Tablets accounted for 47.9% ODF prescribed for infants and toddlers compared to 76.8% in older children. This was reversed for syrups: 46.9% for infants and toddlers compared to 20% for older children.

Table 1. Type of oral dosage forms administered to children under the age of 12 years.

Age category* Tablet N (%) Capsule N (%) Syrup N (%) Suspension N (%) Powder** N (%) Total N (%)
Infants and toddlers 187 (47.9) 0 (0) 183 (46.9) 14 (3.6) 6 (1.5) 390 (100)
Preschool children 395 (60.8) 1 (0.2) 228 (35.1) 23 (3.5) 3 (0.5) 650 (100)
School age children 688 (90.5) 4 (0.5) 55 (7.2) 10 (1.3) 3 (0.5) 760 (100)
Total 1270 (70.5) 5 (0.3) 466 (25.9) 47(2.6) 12 (0.7) 1800 (100)

*Children were categorized based on age as term new-born (0–27 days), infants and toddlers (1 month to 23 months) pre-school children (2–5 years) and school children (6–11 years)

**Powders were extemporaneously prepared and dispensed by the pharmacist at the pharmacy

Percentages may not sum to 100% due to rounding of numbers

Indicator 1: Percentage of instances where the child swallowed the intact tablet/ capsule

The above indicator was calculated to be 57% (95% CI: 54% -60%). Required data were obtained from 1287 solid ODFs.

Out of 552 oral dosage forms that were not swallowed intact 442 [80% (95% CI: 76%-83%] were given to children under the age of six. As shown in Fig 1, 250 of the 552 ODFs that were not taken as intact tablet and were taken solely due to the administration difficulty to swallow the whole tablet. They were either split or crushed. Out of the manipulated tablet/capsule 22% were with narrow therapeutic index.

Fig 1. Reasons for administering manipulated ODFs children.

Fig 1

Indicator 2: Percentage of instances where crushed tablet was dissolved and administered

The above indicator was calculated to be 32% (95% CI: 29%- 34%). Required data to calculate this indicator were obtained from 1287 solid ODFs. Out of 411 ODFs which were crushed 12 ODFs were crushed by pharmacist when dispensing and others by the parent /caregiver at the home setting. Hydrocortisone (50%) and propanol (25%) were two oral dosage forms that were frequently crushed and dispensed as powder sachets by pharmacists whereas vitamins (51%, 95% CI: 47%-56%) were frequently crushed by the parents /caregivers. Parents/ caregivers also had to crush tablets of paracetamol, carbamazepine, sodium valproate, hydrochlorothiazide, thyroxin, hydrocortisone and fludrocortisone.

Crushed tablets were dissolved in water (80.3%), milk (14.4%), other liquid medications (4.1%) and other liquids (1.2%).

Indicator 3: Percentage of liquid oral dosage forms administered using an oral syringe

The above indicator was calculated to be 8% (95% CI: 6%-11%). Required data to calculate this indicator were obtained from 513 liquid ODFs. Commercially available measuring cups followed by the droppers were the commonly used measuring devices to give liquid dosage forms (Fig 2). Only less than 1% has used household spoons.

Fig 2. Measuring devices used by children under the age of 12 years to administer liquid dosage forms.

Fig 2

Indicator 4: Percentage of instances where safe water was used in preparing the medicine

The above indicator was calculated to be 83% (95% CI: 78%-87%). Data to calculate this indicator were obtained from 330 instances where water was required to prepare the medications. The rest of the instances tube well water (2.4%) and well water (14.5%) was used.

Indicator 5: Percentage of instances where the prescribed dose is correctly completed

The above indicator was calculated to be 98.8% [95% (CI; 98%-99%)]. Required data to calculate this indicator were obtained from 1800 ODFs.

The summary of the indicator values is given in Table 2.

Table 2. Summary of the indicator values.

Indicator Ideal value (%) Calculated value (%)
1 Percentage of instances where the child swallowed the intact tablet/capsule 100 57
2 Percentage of instances where crushed tablet was dissolved and administered 0 32
3 Percentage of liquid oral dosage forms administered using an oral syringe 100 8
4 Percentage of instances where safe water was used in preparing the medicine 100 83
5 Percentage of instances where the prescribed dose is correctly completed 100 98.8

Reason for repeating the dose. Out of 115 instances where the dose was repeated the child spitting in the first instances was 83%. This was observed five times more in children under the age of 6 years compared to school children.

Discussion

This study has explored the challenges encountered during administration of ODFs medications to young children in a resource-limited country. Furthermore, we were able to document the prevalence of the rational use of ODFs in a large scale study which is expected to add to the limited evidence available in the literature. The majority of the studies in the literature have described the challenges with no uniform indicators [8, 9]. However, in this study, we were able to document the challenges in an objective way facilitating repeat studies after any form of intervention and comparing the status with the other settings.

A little under half (43%) of the children in our study did not swallow the solid ODFs intact.This was almost in agreement with Tanzanian study (52%) [10]. Due to medications available as unsuitable dosage forms, parents and pharmacists are compelled to manipulate the solid ODFs frequently. Even if the medications are available in suitable dosage forms, they had to be split or crushed because most of them are available only in adult size. The problems documented in our study such as crushing/breaking pill, swallowing the dry powder from crushed pill, drinking crushed/dissolved pill mixed with water appears to be occurring in other resource limited countries as well [11, 12]. Splitting or crushing the tablets poses the risk of administering an inaccurate dose, which could contribute to either over or under dosing. However, it has the potential to cause significant clinical outcome if the drug concern has a narrow therapeutic index. Several studies have shown that quality of such manipulated product is unpredictable [13, 14] There are instances where young children were given manipulated solid dosage forms despite the availability of liquid dosage forms. Reasons for such practice were cost minimisation and children refusing to take liquid dosage forms because of poor palatability. This was documented by other researchers also [15]. Parents, therefore, resort to manipulate the solid dosage forms rather than giving liquid medicines to children, without realizing the problems related to stability, bioavailability and dose accuracy when solid dosage forms are manipulated [16]. This is one of the reason why flexible solid dosage forms are now been promoted as suitable dosage form for young children.

Though oral syringes are recommended when oral liquid dosage forms are prescribed in doses other than multiples of 5 mL [17] this is not regularly practised in our country, compelling the parents to use measuring cups or spoons. It was observed that the pharmacists were also providing measuring cups when dispensing liquid medicines. Even though measuring cups and spoons are better than domestic measuring devices, studies have reported that even pharmacists were not able to measure the dose accurately with measuring cups or spoons. Regulatory authorities should demand that an oral syringe to be provided with liquid dosage forms of medicines which could be prescribed in doses other than multiples of 5 mL. This is critical for medications with narrow therapeutic index where small inaccuracy in doses could lead to toxicity or therapeutic failure and antibacterial agents which should be in a consistent steady state concentration at the site of infection.

Drinking unclean water puts children at risk. As children’s bodies are not as strong as adults, drinking unsafe water puts children in danger of deadly bouts of diarrhoea, parasites and other water related diseases [18]. The use of safe water in our survey was found to be better (75%) than the Tanzanian (41%) survey [10]. This indicator can be further improved by educating the parents. In agreement with several studies in the literature the problems of ODF tends to be high in young children (under 6 years) [19, 20]. The reasons are numerous: children’s growing awareness, children’s swallowing ability. Since these children may not be able to understand the medications and disease we recommend parental education is important. This can take in the form of posters which can be placed in child clinics so that parents can read and understand during the waiting time. Parents could be given illustrated information leaflets with instructions and pictures to keep with them and practice when the need arises.

The study was limited to children who were receiving treatment from a single large hospital. Hence, results may not be generalizable for the entire country. However, it is highly unlikely that the indicators would be higher than what we have reported from a teaching hospital. Repeating this study in other settings would confirm our findings while also documenting the challenges and exploring the areas that were not covered in this study. We have limited the study to calculate the indicators in order to highlight the incorrect administration practices in paediatric pharmacotherapy, hence we did not look at demographics, adherence, number of children in the household and potential determinants of correct administration practice. Further studies should be done to explore the predisposing factors for inappropriate administration of medications to children by parents.

Conclusion

Administration practices of ODFs of medications to children have room for improvement. Parents are compelled to manipulate the available dosage forms due to required dose and administration difficulty. Necessity of age appropriate dosage forms needs to be re-looked by the authorities. Even though oral syringes are used in developing countries to administer liquid dosage forms the use is very less in this setting. Oral syringes should be provided at least to children who are on medications with narrow therapeutic index. Overdosing the medications with narrow therapeutic index can result in life-threatening adverse drug events, whereas under dose errors lead to decreased therapeutic effects. Safe water is accessible to most of the children. Healthcare professionals need to be aware of the risk of wrong administration practices by parents /caregivers of children and educate them.

Supporting information

S1 Table. Data collection sheet-administration indicators.

(DOCX)

Data Availability

The data relevant to this study are available from OSF at https://osf.io/gp9js/?view_only=48a38d05a6cb4f5cb7e39e4dd302e3d5.

Funding Statement

Author who receieved the award: NA. Grant No: UGC/DRIC/PG/2015(ii)/SJP/01 Funder: University Grants Commision,Sri Lanka. URL: https://www.ugc.ac.lk/ Funder didn't play any role in study design,data collection and analysis ,decision to publish or preparation of the manuscript.

References

  • 1.Nadeshkumar A, Sathiadas G, Sri Ranganathan S. Rational dispensing of oral dosage forms of medicines to children at a teaching hospital in Sri Lanka. BMC Health Services Research. 2020; 20:377. 10.1186/s12913-020-05246-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Nadeshkumar A, Sathiadas G, Sri Ranganathan S. Rational Prescribing of Oral Dosage Forms of Medicines to Children at a Teaching Hospital in Sri Lanka. The Pharmaceutical Journal of Sri Lanka.2020. 10(1): 31–42. 10.4038/pjsl.v10i1.51 [DOI] [Google Scholar]
  • 3.World Health Organization. How to investigate drug use in health facilities: Selected drug use indicators 1993; Available from: http://apps.who.int/medicinedocs/en/d/Js2289e/. Accessed October 1 2019 [Google Scholar]
  • 4.Nadeshkumar A, Sathiadas G, Pathmeswaran A, Ranganathan SS. Prescribing, dispensing and administering indicators to describe rational use of oral dosage forms of medicines given to children. WHO South-East Asia J Public Health.2019; 8(1):42–49. doi: 10.4103/2224-3151.255349 [DOI] [PubMed] [Google Scholar]
  • 5.European Medicines Agency Committee for Medicinal products for Human use. Reflection paper: formulations of choice for the paediatric population. 2006. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf. [Google Scholar]
  • 6.Ground water foundation. https://www.groundwater.org/get-informed/basics/wells.html
  • 7.United Nations. The Climate Technology Centre and Network. https://www.ctc-n.org/technologies/boreholes-and-tubewells
  • 8.Ali R., Shadeed A., Fitian H. et al. The difficulties experienced during the preparation and administration of oral drugs by parents at home: a cross-sectional study from Palestine. BMC Pediatr. 2020; 20:198. doi: 10.1186/s12887-020-02105-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Galande AD, Khurana NA, Mutalik S. Pediatric dosage forms—challenges and recent developments: A critical review. J Appl Pharm Sci, 2020; 10(07):155–166. [Google Scholar]
  • 10.Adams L V, Craig SR, Mmbaga EJ et al. Children’s medicines in Tanzania: a national survey of administration practices and preferences. PLoS One 2013;8(3):e58303. doi: 10.1371/journal.pone.0058303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kernell JW, DePaola RV, Maglione AM, Ahern LN, Penney NG, Addiss DG. Risk of adverse swallowing events and choking during deworming for preschool-aged children. PLoS Negl Trop Dis. 2018. Jun 22;12(6):e0006578. doi: 10.1371/journal.pntd.0006578 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodiumfalciparum Malaria.Quique Bassat, Bernhards Ogutu, Abdoulaye Djimde, Kirstin Stricker, Kamal Hamed. Antimicrobial Agents and Chemotherapy Jul 2015, 59 (8) 4366–4374; doi: 10.1128/AAC.00014-15 [DOI] [PMC free article] [PubMed]
  • 13.Teng J, Song CK, Williams RL, Polli JE. Lack of medication dose uniformity in commonly split tablets. Journal of the American Pharmaceutical Association 2002; 42(2):195–199. doi: 10.1331/108658002763508489 [DOI] [PubMed] [Google Scholar]
  • 14.McDevitt JT, Gurst AH, Chen Y. Accuracy of tablet splitting. Pharmacotherapy.1998;18(1):193–7. [PubMed] [Google Scholar]
  • 15.Skwierczynski C, Conroy S. How long does it take to administer oral medicines to children? Paediatric and Perinatal Drug Therapy. 2008;8:145–9 [Google Scholar]
  • 16.Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opinion on Drug Delivery. 2007; 4:37–45. doi: 10.1517/17425247.4.1.37 [DOI] [PubMed] [Google Scholar]
  • 17.Joint Formulary Committee. BNFc: September 2018–19. London: Pharmaceutical Press
  • 18.World Vision. https://www.wvi.org/laos/article/drinking-unclean-water-puts-children-risk
  • 19.Nunn T, Williams J. Formulation of medicine for children July 2005. British Journal of Clinical Pharmacology.59 (6):674–6. doi: 10.1111/j.1365-2125.2005.02410.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hoppu K, Sri Ranganathan S, Dodoo AN. Realities of paediatric pharmacotherapy in the developing world. Arch Dis Child. 2011. Aug;96(8):764–8. doi: 10.1136/adc.2009.180000 Epub 2011 Mar 25 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Vijayaprakash Suppiah

6 Apr 2022

PONE-D-21-27919Administering of oral dosage forms of medicines to children in a resource limited settingPLOS ONE

Dear Dr. Nadeshkumar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 21 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Vijayaprakash Suppiah, PhD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf".

2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for the opportunity to review your manuscript regarding safe and appropriate administration of oral formulations to infants and young children.

Here are my comments:

1. English is a tricky language. Your manuscript would be greatly improved by having a native English speaker review and revise the wording and sentence structure. For example, administration vs administering is the appropriate word in the title;

Consider changing to: Administration of oral medication dosage forms to children in a limited resource setting (better flow in common English language)

2. Please define all abbreviations upon first use e.g. ODF, and terms such as safe water, well water, and tube well water in the first part of the paper and risks of unsafe water to dissolve oral medications.

4. The procedure for selection of the prescriptions for review in the study is unclear. This section requires revision with clear inclusion and exclusion criteria, listing the dates of the study period, and ages of patients 0- 12 years?

Was the medication prescribed for a minimum of 1 month or < 1 month? Please clarify in procedure.

5. Was adherence to the prescription evaluated? - goal of oral dosage forms that can be easily administered and tolerated, correct?

6. Was there a difference in patient practice if they had one child vs > 1 child? Would be interesting to compare these groups

7. Were all oral medications included in this study able to be safely crushed? Please refer to ISMP list Medications that should not be crushed: updated in 2021 https://www.ismp.org/recommendations/do-not-crush

8. Did you collect demographics beyond age of children? How about diagnoses, area of residence (urban vs rural?), etc

9. Moving beyond descriptive statistics, consider regressions examining factors associated with appropriate oral dosage administration for a more meaningful impact on practice. Which authors were involved in the analysis?

10. Discussion, regarding need for printed education for parents (is there a literacy issue?), how about "teach back" method

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Victoria Tutag Lehr, Pharm D Professor Pharmacy Practice Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, Detroit MI 48201

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Dec 22;17(12):e0276379. doi: 10.1371/journal.pone.0276379.r002

Author response to Decision Letter 0


15 Jun 2022

Dear Editor,

We would like to thank you and the reviewer for careful and thorough reading of this manuscript and for the comments and positive suggestions. Our response to each point raised are given below and the corrections are highlighted in the revised manuscript.

Thanking you.

Yours Sincerely,

Abarna Nadeshkumar

(Corresponding author)

Response from authors to the comments

1) Responses to the comments from Academic Editor

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Author’s Response: Thank you very much. We apologize for not following the journal style. We have now revised the whole manuscript based on the journal style

2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

Author’s Response: The copy of the questionnaire is given as supporting information

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter

Author’s Response: Thank you and the data set will be made available as requested if accepted for publication.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Author’s Response: Thank you and the data set will be made available as requested if accepted for publication.

2) Responses to the comments from Reviewer

1. Reviewer Comment: English is a tricky language. Your manuscript would be greatly improved by having a native English speaker review and revise the wording and sentence structure. For example, administration vs administering is the appropriate word in the title;

Consider changing to: Administration of oral medication dosage forms to children in a limited resource setting (better flow in common English language)

Author’s Response: Taking into consideration reviewer´s comment, we thoroughly revised the manuscript and corrected the manuscript.

We have amended the term administering to administration and we have amended the title also as suggested

2. Reviewer Comment : Please define all abbreviations upon first use e.g. ODF, and terms such as safe water, well water, and tube well water in the first part of the paper and risks of unsafe water to dissolve oral medications.

Author’s Response:

I. Abbreviations are defined in the first use (Line numbers 56, 57, 95) and terms are defined in the data analysis section.

II. Definitions for the terms are given below.(Added in the data analysis section )

Well water- water from hole drilled into the ground to access water contained in an aquifer. Water is supplied through a water pump (Line number 115)

Tube well water- water obtained through a narrow screened tube, pipe or casing that is driven into a subsurface aquifer. (Line number 116)

III. Risks of unsafe water to dissolve oral medications in given in the discussion. (Line number 226 )

3. Reviewer Comment: The procedure for selection of the prescriptions for review in the study is unclear. This section requires revision with clear inclusion and exclusion criteria, listing the dates of the study period, and ages of patients 0- 12 years?

Author’s Response: Thank you. Inclusion exclusion criteria and the data study period have been added to the manuscript.

1) Inclusion exclusion criteria (Line number 73 under methods)

Inclusion criteria

I. Prescriptions which had been prescribed with at least one oral dosage form of medicine within a month from the day of data collection to children under the age of 12 years

II. Parents/ guardians giving the data were the ones who gave medicines to the child at home

III. Parents/ guardians should have the prescriptions with them at the time of data collection.

Exclusion criteria

I. Prescriptions without oral dosage forms.

II. Prescriptions issued. older than one month

2) Dates of study period (Line number 66 under methods)

January 2017 to January 2019

3) Ages of patients- Line number 110

Data from term new born [child born on the day of data collection (0 day)] up to 12 years were collected. They were categorized as term new-born (0-27 days), infants and toddlers (1 month to 23 months) pre-school children (2-5 years) and school children (6-11 years)

Reviewer Comment: Was the medication prescribed for a minimum of 1 month or < 1 month? Please clarify in procedure.

Author’s Response: Data were collected when the prescription was prescribed within one month before the day of data collection. Eg if the data was collected on 1st February 2017, prescriptions prescribed between 1st January 2017 to 31st January 2017 were considered. (Line number 63)

4. Reviewer Comment: Was adherence to the prescription evaluated? - goal of oral dosage forms that can be easily administered and tolerated, correct?

Author’s Response: We regret to inform you that we did not evaluate the adherence to prescriptions however we evaluated whether the dose was completed or not and the reasons for repeating the dose.

5. Reviewer Comment: Was there a difference in patient practice if they had one child vs > 1 child? Would be interesting to compare these groups

Author’s Response: Sorry, we didn’t not collect the data on number of children

6. Reviewer Comment: Were all oral medications included in this study able to be safely crushed? Please refer to ISMP list Medications that should not be crushed: updated in 2021 https://www.ismp.org/recommendations/do-not-crush

Author’s Response: ISMP list is given in brand names which are mostly not available in Sri Lanka. Unfortunately we collected only the generic names during the data collection. Brand names of the medicines administered by parents at the time of data collection were not known. In resource limited countries like Sri Lanka due to non-availability of required strength and age appropriate dosage forms for young children, health care professionals and parents are compelled to crush the available adult tablet without knowing any data on bioavailability, safety, palatability and dose accuracy (Somasiri, U., Thillainathan, S., Fernandopulle, R. and Sri Ranganathan, S., 2013. Antiepileptic drugs for children: Availability, suitability and acceptability. Sri Lanka Journal of Child Health, 42(1), pp.38–39 , Hoppu K, Sri Ranganathan S, Dodoo AN. Realities of paediatric pharmacotherapy in the developing world. Arch Dis Child. 2011 Aug;96(8):764-8. doi: 10.1136/adc.2009.180000. Epub 2011 Mar 25. PMID: 21441240.)

7. Reviewer Comment: Did you collect demographics beyond age of children? How about diagnoses, area of residence (urban vs rural?), etc

Author’s Response: No, we did not collect demographics beyond age

8. Reviewer Comment: Moving beyond descriptive statistics, consider regressions examining factors associated with appropriate oral dosage administration for a more meaningful impact on practice. Which authors were involved in the analysis?

Author’s Response: We agree with your comments. Regression analysis would have greatly improved our paper, however examining the factors associated with appropriate oral dosage administration was not an objective of this paper. This study was aimed to describe the administration practices using the indicators .We did not focus on the factors affecting the practices in this study. After documenting the extend of problem we are in the process developing a further study to look in to the factors.

First author was involved in the analysis.

14. Reviewer Comment: Discussion, regarding need for printed education for parents (is there a literacy issue?), how about "teach back" method

Author’s Response: Luckily, there is no literacy issues with regard to native language in Sri Lanka. The literacy rate of Sri Lanka is above 90%. In our personnel experiences we have noticed that both the doctors and the pharmacists as well as the parents don’t have time to give or listen to advices. The clinics and the pharmacies are usually overcrowded and the waiting time to get the service is long. Hence we hypothesized that printed education materials which can be displayed in the clinics and distributed to parents while they are waiting to receive the service will be a suitable intervention

Decision Letter 1

Vijayaprakash Suppiah

4 Jul 2022

PONE-D-21-27919R1Administration of oral dosage forms of medicines to children in a resource limited settingPLOS ONE

Dear Dr. Nadeshkumar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 18 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Vijayaprakash Suppiah, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for allowing me to review this revised manuscript. While much improved there are some persistent areas that require attention and revision:

1)Inclusion exclusion criteria (Line number 73 under methods)

Inclusion criteria

I.Prescriptions which had been prescribed with at least one oral dosage form of

medicine within a month from the day of data collection to children under the age of 12

years (dispensed may be a more definite word here vs prescribed?) Medication is the usual term vs medicine

II.Parents/ guardians giving the data were the ones who gave medicines to the child at

home (giving suggest change to providing)

III.Parents/ guardians should have the prescriptions with them at the time of data

collection. (recommend change "should" to must to strengthen the inclusion criteria)

Exclusion criteria

I.Prescriptions without oral dosage forms.

II.Prescriptions issued. older than one month (recommend change this sentence-doesnt make sense in current form. Suggest something similar to "Prescriptions dispensed more than 30 days prior to data collection"

Please re-review the entire manuscript carefully for correct grammar and typos

Again, suggest review by a native English speaker, perhaps not involved in the study to obtain a clear concise edited text

There are persistent grammatical and a spelling error

Please see lines 72, 194,200,206, 226,228 for revision

With respect to regression analysis, this recommendation was rejected based on that this was not in the original study question, however it may strengthen the study. If you do not wish to run the regression to provide a robust analysis of this issue, then please discuss the need to explore factors predisposing to inappropriate administration of medications by parents to children in your discussion. Thank you.

Clearly state in the Discussion section exactly how information to parents/caregivers in a busy clinic with long wait times can be provided (printed information on posters, handouts, etc)

Recommend stating clearly in a section on limitations that demographics, adherence and number of children in the household were not evaluated

When writing about the incorret use of medication dispensing devices and drugs of narrow therapeutic index, please specify the proportion of your study drugs where of this nature...for example in a regional referral center, children may receive anticoagulants, antiarryhmics, antiepileptics that require exact dosage administration

Finally, in the conclusion when stating issues, strongly recommend that some of these are stated...such as disease transmission, bioavailability, and over and underdosing. The current conclusion is rather weak.

Good luck in your final revisions!

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Dec 22;17(12):e0276379. doi: 10.1371/journal.pone.0276379.r004

Author response to Decision Letter 1


6 Sep 2022

1. Reviewer’s Comment: Thank you for allowing me to review this revised manuscript. While much improved there are some persistent areas that require attention and revision:

1)Inclusion exclusion criteria (Line number 73 under methods)

Inclusion criteria

I. Prescriptions which had been prescribed with at least one oral dosage form of

medicine within a month from the day of data collection to children under the age of 12

years (dispensed may be a more definite word here vs prescribed?) Medication is the usual term vs medicine

Author’s response: Thank you for the comment. I have changed the word prescription into dispensing (Line number 74) and the word medicine in to medication (Entire manuscript)

2. Reviewer’s Comment: Parents/ guardians giving the data were the ones who gave medicines to the child at home (giving suggest change to providing)

Author’s response: Thank you for the comment. The wording has been changed to providing (Line number 76).

3. Reviewer’s Comment: Parents/ guardians should have the prescriptions with them at the time of data collection. (recommend change "should" to must to strengthen the inclusion criteria)

Author’s response: The wordings has been changed to must (Line number 78) .

4. Reviewer’s Comment: Exclusion criteria

I. Prescriptions without oral dosage forms.

II. Prescriptions issued. Older than one month (recommend change this sentence-doesn’t make sense in current form. Suggest something similar to "Prescriptions dispensed more than 30 days prior to data collection"

Author’s response: The recommended change has been done (Line number 82).

5. Reviewer’s Comment: Please re-review the entire manuscript carefully for correct grammar and typos

Again, suggest review by a native English speaker, perhaps not involved in the study to obtain a clear concise edited text

There are persistent grammatical and a spelling error

Please see lines 72, 194,200,206, 226,228 for revision

Author’s response: Entire manuscript was re reviewed for grammar and typos and the lines 74,200,205,211,233,235 were revised.

6. Reviewer’s Comment: With respect to regression analysis, this recommendation was rejected based on that this was not in the original study question, however it may strengthen the study. If you do not wish to run the regression to provide a robust analysis of this issue, then please discuss the need to explore factors predisposing to inappropriate administration of medications by parents to children in your discussion. Thank you.

Author’s response: Thank you for your comment. It has been discussed in the discussion (Line number 250).

7. Reviewer’s Comment: Clearly state in the Discussion section exactly how information to parents/caregivers in a busy clinic with long wait times can be provided (printed information on posters, handouts, etc)

Author’s response: Thank you for your comment. It has been discussed in the discussion (Line number 237).

8. Reviewer’s Comment : Recommend stating clearly in a section on limitations that demographics, adherence and number of children in the household were not evaluated

Author’s response: Limitation has been clearly stated in the discussion now. (Line number 246).

9. Reviewer’s Comment: When writing about the incorrect use of medication dispensing devices and drugs of narrow therapeutic index, please specify the proportion of your study drugs where of this nature...for example in a regional referral center, children may receive anticoagulants, antiarryhmics, antiepileptics that require exact dosage administration

Finally, in the conclusion when stating issues, strongly recommend that some of these are stated...such as disease transmission, bioavailability, and over and under dosing. The current conclusion is rather weak.

Good luck in your final revisions!

Author’s response: Proportion of the study drug has been mentioned (Line numbers 145,155 .The conclusion has been rewritten. (Line number 252

Attachment

Submitted filename: Reponses to Reviewers comments .docx

Decision Letter 2

Vijayaprakash Suppiah

6 Oct 2022

Administration of oral dosage forms of medicines to children in a resource limited setting

PONE-D-21-27919R2

Dear Dr. Nadeshkumar,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Vijayaprakash Suppiah, PhD

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you again for the opportunity to review your second version of edits

Overall, the much improved and I recommend that the manuscript be accepted for publication with two minor grammatical revisions:

Line 256: re-looked -a better word may be "re-examined"

Line 257: very less - please change to "less"

(do not require the "very")

Good luck with your future work

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Acceptance letter

Vijayaprakash Suppiah

14 Dec 2022

PONE-D-21-27919R2

Administration of oral dosage forms of medicines to children in a resource limited setting

Dear Dr. Nadeshkumar:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Vijayaprakash Suppiah

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Data collection sheet-administration indicators.

    (DOCX)

    Attachment

    Submitted filename: Reponses to Reviewers comments .docx

    Data Availability Statement

    The data relevant to this study are available from OSF at https://osf.io/gp9js/?view_only=48a38d05a6cb4f5cb7e39e4dd302e3d5.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES